Speech Date

2025/03/25

Theme

Announcement on Behalf of Important Subsidiary CMC Regarding the Cumulative Acquisition of Certificates of Financial Products Reaching the Disclosure Threshold

Fact Date

2025-03-25

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Structured Deposit of Bank of Hangzhou (China)
2.Date of occurrence of the event:2025/02/26~2025/03/25
3.Volume, unit price, and total monetary amount of the transaction:
This purchase is for RMB. 10,000,000
The total cumulative purchase is RMB 35,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Bank of Hangzhou (China) (Non-related party)
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:None
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:None
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):None
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:One-time payment
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Expected Annualized Return of the Product as Announced by the Bank.
Processed according to the company’s approval authority.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative holding amount:RMB 35,000,000
Restricted rights: RMB 0
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.26%
Percentage of equity of parent company: 5.62%
Working capital: NTD 4,195,291 thousand
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
RMB Structured Deposit
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:None
18.Date of the Board of Directors’ resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
21.Name of the CPA firm:None
22.Name of the CPA:None
23.License no.of the CPA:None
24.Whether the transaction involved in change of business model:None
25.Details on change of business model:None
26.Details on transactions with the counterparty for the past
year and the expected coming year:Plan according to the overall financial
condition of the group, following the procedures for asset acquisition
or disposal.
27.Source of funds:Operating funds
28.Any other matters that need to be specified:None

Speech Date

2025/03/17

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. to hold 2024 annual performance conference

Fact Date

2025-03-25

Describe

1.Date and time that the Company disclose its financial
or business information to the public:2025/03/25
2.Location that the Company disclose its financial or
business information to the public:Web conference
3.Financial/Business data to be disclosed:
Operating results and financial position for the financial year 2024
4.Content of press release, if provided:NA
5.Any other matters that need to be specified:
Date and time of conference：2025/3/25(February) 11:30-12:30
Online platform：https://www.ir-online.cn
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/03/11

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the year of 2024

Fact Date

2025-03-11

Describe

1.Date of the board of directors submitted or approved:2025/03/11
2.Date of the audit committee approved:2025/03/11
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):4,192,722
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):791,521
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):97,132
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):88,922
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):47,997
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):629
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.01
11.Total assets end of the period (thousand NTD):6,958,441
12.Total liabilities end of the period
(thousand NTD):1,764,130
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,798,820
14.Any other matters that need to be specified:None

Speech Date

2025/03/11

Theme

Announcement of Board of Directors' Resolution Not to Distribute Dividends

Fact Date

2025-03-11

Describe

1.Date of the board of directors resolution:2025/03/11
2.Year or quarter which dividends belong to :2024
3.Period which dividends belong to:2024/01/01~2024/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10

Speech Date

2025/03/11

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2025-03-11

Describe

1.Date of occurrence of the event:2025/03/11
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2024 Annual Report and its Summary
of the Company
2、Resolutions Regarding the 2024 Board of Directors' Work Report
of the Company
3、Resolutions Regarding the 2024 Independent Directors' Performance Report
of the Company
4、Resolutions Regarding the Self-assessment of Independence of
Independent Directors
5、Resolutions Regarding the 2024 General Manager's Work Report
of the Company
6、Resolutions Regarding the 2024 Audit Committee's Performance Report
of the Company
7、Resolutions Regarding the Performance Evaluation Report of the
Accounting Firm for the Year 2024 and the Report on the Supervisory
Duties Performed by the Audit Committee
8、Resolutions Regarding the 2024 Financial Statements Report of the Company
9、Resolutions Regarding the 2024 Internal Control Evaluation Report of the
Company
10、Resolutions Regarding the Special Report on the Utilization of Raised
Funds and its Actual Usage in 2024
11、Resolutions Regarding the termination of certain fundraising projects
and the reallocation of remaining Raised Funds for permanent
supplementation of working capital.
12、Resolutions Regarding the 2025 Audit Plan of the Company
13、Resolutions Regarding the amendment of the remuneration management
system for directors and supervisors.
14、Resolutions Regarding the 2025 Remuneration Plan for the company's
directors of the Company
15、Resolutions Regarding the 2025 Compensation Plan for Senior Management
Personnel of the Company
16、Resolutions Regarding the Proposed Profit Distribution Plan for the
Year 2024
17、Resolutions Regarding the Plan for the Guarantee Quota for the Year 2025
of the Company
18、Resolutions Regarding the company's application for credit facilities
from banks and other financial institutions.
19、Resolutions Regarding the company's use of temporarily idle self-owned
funds for entrusted wealth management.
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2025/03/11

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolution by the Board of Directors to distribute dividends

Fact Date

2025-03-11

Describe

1.Date of the board of directors resolution:2025/03/11
2.Type and monetary amount of dividend distribution:
Cash Dividends RMB$ 19,902,631.65(tax included)
3.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/03/05

Theme

Announcement of the board's approval for donation to related party

Fact Date

2025-03-05

Describe

1.Date of occurrence of the event:2025/03/05
2.Reason for the donation:Support for Social Welfare
3.Total amount of the donation:NT$60 thousand
4.Counterparty to the donation:Association for Contemporary
Medicine and Management (ACMM)
5.Relationship with the company:The Chairman of the Company
serves as its Honorary Secretary-General
6.Name and resume of independent director(s) that expressed
an objection or qualified opinion:None
7.Objection or qualified opinion by the aforementioned
independent director(s):None
8.Any other matters that need to be specified:
The authority for this donation is fully delegated to the chairman to
execute from January 1, 2025 to December 31, 2025.

Speech Date

2025/03/05

Theme

Board of Directors resolved to convene the 2025 Annual General Shareholders’Meeting

Fact Date

2025-03-05

Describe

1.Date of the board of directors resolution:2025/03/05
2.General shareholders' meeting date:2025/05/20
3.General shareholders' meeting location:Cowealth Center of 23F, No. 76,
Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:
(1)2024 annual business report
(2)Audit Committee's review of the 2024 annual final accounting books
and statements
(3)Report on 2024 employees' and directors' remuneration
(4)Report on 2024 director compensation
6.Cause for convening the meeting II.Acknowledged matters:
(1)2024 annual financial statements and business report
(2)2024 earnings distribution
7.Cause for convening the meeting III.Matters for Discussion:
(1)Amendments to the ”Articles of Association”
(2)Amendments to the ”Procedures for Loaning of Funds to Others”
8.Cause for convening the meeting IV.Election matters:None
9.Cause for convening the meeting V.Other Proposals:None
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2025/03/22
12.Book closure ending date:2025/05/20
13.Any other matters that need to be specified:
In accordance with the laws of the Republic of China, the following matters
related to the acceptance of shareholder proposals in writing are
established:
(1)Acceptance period: from March 7, 2025 to March 17, 2025.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Allied Healthcare Medical
Equipment Co., Ltd., a company incorporated in the Cayman Islands.
(4) Proposal Eligibility: Shareholders who hold more than 1%
of the total issued shares (whether individually or collectively).
(5) Proposal Method: Proposals must be submitted in writing and limited to
one proposal per shareholder. If more than one proposal is submitted,
none will be considered. Proposals submitted by shareholders are limited to
300 words.Proposals exceeding 300 words will not be included in the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters not covered
regarding shareholder proposals will be handled according to relevant laws
and regulations. Whether or not a proposal will be excluded from the agenda
according to the company’s articles of association will be reviewed by
the board of directors after the proposal acceptance period has ended.
The detailed content of the accepted proposals will be based on the
company’s public announcements on the MOPS.
For this shareholder meeting, shareholders will exercise their voting rights
electronically. Relevant details are as follows:
(1) Voting Period: From April 20, 2025, to May 17, 2025.
(2) Electronic Voting Platform: Taiwan Depository & Clearing Corporation,
website: https://www.stockvote.com.tw

Speech Date

2025/03/05

Theme

Announcement pursuant to §22 I subpara. 1 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-03-05

Describe

1.Date of occurrence of the event:2025/03/05
2.The public company or its subsidiaries for which
the amount of monetary loans extended to others reaches
20 percent or more of their net worth on the latest
financial statements(1)Name of funding recipient
(2)Relationship with lender(3)Lending limit
(thousand NTD)(4)Outstanding balance (thousand NTD)
up to the date of occurrence(5)Reason for lending
up to the date of occurrence:
(1)Name of funding recipient:Cowealth Medical Tianjin Co., Ltd.
(2)Relationship with lender:
Lender: Cowealth Medical China Co., Ltd.
100% direct and indirect subsidiaries of the company
(3)Lending limit (thousand NTD):2,106,410
(4)Outstanding balance (thousand NTD) up to the date of occurrence:2,246
(5)Reason for lending up to the date of occurrence:Operating Capital
3.The total amount of monetary loans extended to others
as of the date of occurrence:2,682,547
4.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.96
5.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds and Financial institutions
6.Any other matters that need to be specified:None

Speech Date

2025/03/03

Theme

Announcement of the Board of Directors meeting date for the Consolidated Financial Report for the year of 2024

Fact Date

2025-03-03

Describe

1.Date of a notice of the board of directors meeting is issued:2025/03/03
2.Expected date of the board of directors meeting is convened:2025/03/11
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:The Consolidated Financial Report for the year of 2024
4.Any other matters that need to be specified:None

Speech Date

2025/02/07

Theme

Announcement on Behalf of Important Subsidiary CMC Regarding the Cumulative Acquisition of Certificates of Deposit Reaching the Disclosure Threshold

Fact Date

2025-02-07

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Certificates of deposit of Fubon Bank (China)
2.Date of occurrence of the event:2025/02/07~2025/02/07
3.Volume, unit price, and total monetary amount of the transaction:
RMB 42,719,166.68
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Fubon Bank (China) (Non-related party)
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:None
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:None
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):None
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:Interest payment upon maturity
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Processed according to the company’s approval authority.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative holding amount: RMB 42,719,166.68
Restricted rights: RMB 0
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.81%.
Percentage of equity of parent company: 6.87%.
Working capital: NTD 4,139,205,000
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
RMB certificates of deposit
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:No
18.Date of the Board of Directors’ resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
21.Name of the CPA firm:None
22.Name of the CPA:None
23.License no.of the CPA:None
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:None
26.Details on transactions with the counterparty for the past
year and the expected coming year:Plan according to the overall financial
condition of the group, following the procedures for asset acquisition
or disposal.
27.Source of funds:Operating funds
28.Any other matters that need to be specified:None

Speech Date

2025/01/14

Theme

Announcement of the Board of Directors approved the change of Financial Officer, Accounting Officer and Acting Spokesperson

Fact Date

2025-01-14

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Financial Officer, Accounting Officer and Acting Spokesperson
2.Date of occurrence of the change:2025/01/14
3.Name, title, and resume of the previous position holder:
(1) Financial Officer: Gao, Heng-Zheng / Accounting Manager (acting)
(2) Accounting Officer: Gao, Heng-Zheng / Accounting Manager (acting)
(3) Acting Spokesperson: Ma, Fang / Internal Audit Officer (acting)
4.Name, title, and resume of the new position holder:
(1) Financial Officer: Tian, Jing/ Finance Director
(2) Accounting Officer: Tian, Jing / Finance Director
(3) Acting Spokesperson: Ma, Fang / Internal Audit Officer
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):New replacement
6.Reason for the change:New replacement
7.Effective date:2025/01/14
8.Any other matters that need to be specified:
The newly appointed individuals were approved for appointment by
the Board of Directors on January 14, 2025.

Speech Date

2025/01/14

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-01-14

Describe

1.Date of occurrence of the event:2025/01/14
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Royal Seal Holding Co., Ltd.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
The company's subsidiaries directly and indirectly hold 100% of the shares
(3)Lending limit (thousand NTD):2,106,410
(4)Starting outstanding balance (thousand NTD):179,452
(5)New loan (thousand NTD):717,808
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:897,260
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):707,751
(2)Cumulative gains/losses (thousand NTD):-135,356
5.Method of calculation of interest:
The maximum interest rate on short-term debt from financial institutions
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):2,606,077
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.93
9.Sources of funds for the company to extend monetary
loans to others:Financial institutions and parent company
10.Any other matters that need to be specified:None